PicoCELA Inc. (NASDAQ:PCLA) Short Interest Update

PicoCELA Inc. (NASDAQ:PCLA) was the recipient of a large growth in short interest during the month of May. As of May 29th, there was short interest totaling 126,693 shares, a growth of 1,375.2% from the May 14th total of 8,588 shares. Approximately 333.4% of the company’s shares are sold short. Based on an average daily volume of 9,565,111 shares, the days-to-cover ratio is currently 0.0 days.

Hedge Funds Weigh In On PicoCELA

An institutional investor recently bought a new position in PicoCELA stock. XTX Topco Ltd acquired a new stake in PicoCELA Inc. (NASDAQ:PCLA) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned 0.16% of PicoCELA as of its most recent filing with the Securities and Exchange Commission.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PicoCELA in a research report on Wednesday, April 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, PicoCELA has a consensus rating of “Sell”.

PicoCELA Price Performance

PicoCELA stock traded down $0.80 during midday trading on Tuesday, reaching $6.50. 21,633 shares of the stock traded hands, compared to its average volume of 4,442,103. The company has a 50-day simple moving average of $3.60 and a two-hundred day simple moving average of $5.15. PicoCELA has a 12-month low of $1.35 and a 12-month high of $112.20. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.57 and a current ratio of 2.13.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.